Summary
Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1–3, every 3 weeks.
Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.
References
Bitran JD, Desser RK, DeMeester TR, Colman M, Evans R, Billings A, Griem M, Rubenstein L, Shapiro C, Golomb HM (1976) Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)-Effective four-drug combination chemotherapy for metastatic-on-óat cell bronchogenic carcinoma. Cancer Treat Rep 60:1225
Cohen MH, Ihde DC, Bunn PA Jr, Fossieck BE, Matthews MJ, Shackney SE, Johnston-Early A, Makuch R, Minna JD (1979) Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 63:163
Eagan RT, Ingle JN, Creagan ET, Frytak S, Kvols LK, Rubin J, McMahon RT (1978) VP16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 62:843
EOTC (European Organization for Research on the Treatment of Cancer, Clinical Screening Group) (1973) Epipodophyllotoxin VP16-213 in treatment of acute leukaemias, haematosarcomas, and solid tumours. Br Med J 3:199
Issel BF (1978) Clinical brochure etoposide (VP16-213). Dept. Clinical Cancer Research, Bristol Lab., Syracuse, New York
Livingston RB, Fee WH, Einhorn LH, Burgess MA, Freireich EJ, Gottlieb JA, Farber MO (1976) BACON (bleomycin, adriamycin, CCNU, oncovin, and nitrogen mustard) in squamous lung cancer. Experience in fifty patients. Cancer 37:1237
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morasca, L., Marsoni, S., Pisoni, M.B. et al. VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. Cancer Chemother. Pharmacol. 7, 209–210 (1982). https://doi.org/10.1007/BF00254551
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254551